---
layout: minimal-medicine
title: Ofatumumab
---

# Ofatumumab
### Generic Name
Ofatumumab

### Usage
Ofatumumab is a monoclonal antibody primarily used in the treatment of chronic lymphocytic leukemia (CLL) and relapsing forms of multiple sclerosis (MS).

In CLL, its uses are multifaceted:

* **Previously untreated CLL:** It's used in combination with chlorambucil when fludarabine-based therapy is unsuitable.
* **Relapsed CLL:**  It's administered with fludarabine and cyclophosphamide.
* **Fludarabine and alemtuzumab-refractory CLL:**  Ofatumumab is an option when the patient hasn't responded to these other treatments.
* **Extended treatment of CLL:** For patients with incomplete or partial responses after at least two prior treatment lines.


In MS, Ofatumumab targets relapsing forms, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.  It helps manage disease activity and reduce the frequency of relapses.


### Dosage

**Important Note:**  The following dosage information is for general knowledge and should not replace consultation with a healthcare professional.  Dosage will be tailored to the individual patient's condition, response to treatment, and other health factors.

**Chronic Lymphocytic Leukemia (CLL):**  Ofatumumab for CLL is administered intravenously (IV).  Dosage varies significantly depending on the treatment phase (previously untreated, relapsed, refractory, or extended treatment).  Specific regimens involving initial doses and subsequent maintenance doses are complex and require precise adherence to a physician's instructions.  Premedication with acetaminophen, an antihistamine, and a corticosteroid is typically given to minimize infusion reactions.


**Multiple Sclerosis (MS):** Ofatumumab for MS is administered subcutaneously (SubQ) using a pre-filled auto-injector pen. The recommended regimen typically starts with weekly injections for the first three weeks, followed by monthly injections thereafter.

**Pediatric Dosage:** The safety and efficacy of Ofatumumab in children have not been established.

**Dosage Adjustments:** Dosage adjustments may be necessary based on factors like renal and hepatic function, and the severity of side effects, especially infusion reactions.  Specific recommendations should come from the treating physician.

### Side Effects

Ofatumumab, like many medications, can cause side effects. The severity and frequency of these can vary among individuals.

**Common side effects (occur in >10% of patients):**

* **CLL:** Fatigue, diarrhea, nausea, skin rash, anemia, neutropenia, infections (bacterial, fungal, viral), bronchitis, cough, dyspnea, pneumonia, upper respiratory tract infection, fever, infusion-related reactions.
* **MS:** Headache, infections, injection-site reactions, upper respiratory tract infection.


**Less common, but potentially serious side effects (occur in 1-10% of patients):**

* **CLL:** Chills, insomnia, hypertension, hypotension, peripheral edema, tachycardia, hyperhidrosis, urticaria, hypogammaglobulinemia, herpes zoster infection, influenza, sepsis, back pain, muscle spasms, nasopharyngitis, sinusitis.
* **MS:** Urinary tract infections, decreased serum immunoglobulins (IgM), back pain.


**Rare but serious side effects (occur in <1% of patients or post-marketing reports):**

* Stevens-Johnson syndrome, porphyria cutanea tarda, tumor lysis syndrome, hepatitis B reactivation (potentially fatal), progressive multifocal leukoencephalopathy (PML) (potentially fatal).

If any concerning side effects occur, promptly consult a healthcare professional.

### How it Works

Ofatumumab is a monoclonal antibody targeting the CD20 protein found on the surface of B lymphocytes (a type of white blood cell).  By binding to CD20, Ofatumumab triggers mechanisms that lead to the destruction of these cells.

In CLL, this targeted destruction helps reduce the number of cancerous B cells, slowing or stopping the disease's progression.

In MS, the mechanism is less fully understood, but it's believed that the reduction of B cells helps modulate the immune system's overactivity that contributes to the inflammation and demyelination characteristic of MS.

### Precautions

* **Hypersensitivity:** Ofatumumab is contraindicated in patients with hypersensitivity to it or its components.
* **Progressive multifocal leukoencephalopathy (PML):**  A serious, often fatal, brain infection is a potential risk; patients with a history of PML should not receive Ofatumumab.  Careful monitoring is needed.
* **Hepatitis B:**  Reactivation of hepatitis B is a significant concern; screening for hepatitis B before starting Ofatumumab is crucial.  Patients with active hepatitis B should not receive this treatment.
* **Infections:** Ofatumumab weakens the immune system, increasing the risk of infections.
* **Live vaccines:**  Avoid live vaccines during and for a period after Ofatumumab treatment.
* **Pregnancy and breastfeeding:**  Discuss the risks and benefits with your doctor. Effective contraception is recommended for women of reproductive age during and after treatment.
* **Drug interactions:**  Inform your doctor about all medications you're taking, as interactions are possible.
* **Renal and hepatic impairment:** Dosage adjustments might be necessary in patients with impaired kidney or liver function.



### FAQs

* **Q: How long does Ofatumumab treatment last?** A: The treatment duration varies greatly depending on the condition and individual response, ranging from several months to years.  Your doctor will determine the appropriate duration.

* **Q: How is Ofatumumab stored?** A:  Storage instructions vary depending on the formulation (IV or SubQ). Always follow the instructions provided with the medication.

* **Q: What should I do if I miss a dose?** A:  Contact your doctor immediately to discuss the missed dose and receive further instructions.  Do not attempt to make up for a missed dose on your own.

* **Q: Are there specific dietary restrictions while taking Ofatumumab?** A: There are typically no specific dietary restrictions, but maintaining a healthy diet is generally advisable.

* **Q: Can I drive or operate machinery while on Ofatumumab?** A: Fatigue is a possible side effect. If affected, avoid tasks requiring alertness until the symptoms subside.

* **Q:  What should I do if I experience an infusion reaction (for IV formulation)?** A: The infusion should be stopped immediately and medical attention sought.


**Disclaimer:** This information is intended for general knowledge and does not constitute medical advice.  Always consult with a healthcare professional before starting or changing any medication.  They can provide personalized guidance based on your specific health needs and medical history.
